RENB Renovaro: Price-to-Projected Revenue Ratio

Brandmark of Renovaro Inc. (RENB)

Renovaro Inc. focuses on developing cancer vaccines using AI, prioritizing scientific advancement over operational stability. The projected price-to-sales ratio exhibits sharp spikes due to the struggle between supply and demand, with the mark reflecting the latest data. The combination of cell therapy and digitalization reduces costs, yet the success of RENB depends on drug trials and high R&D expenditure.

RENB Enochian BioSciences: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Renovaro Biosciences (RENB)

- current price and projected stock value:
- company stock capitalization data:
Summary company analysis:RENB (Enochian BioSciences)
Product sample of Renovaro

The integration of AI into cancer vaccine synthesis at Renovaro Inc. (RENB) is accelerating R&D, which is reflected in the high volatility of the forward P/S ratio. This indicator compares market capitalization with expected revenue, revealing an imbalance between speculative demand and actual sales volume, where sharp fluctuations in the multiple signal the potential for rapid gains alongside an increased risk of capital drawdown.

Competitor analysis

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Forward P/S Multiple artivabio.com|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Limited)|Veru - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio xiliotx.com (XLO)|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple